IL23A and neoplasm: KEGG enrichment analysis demonstrated a significant alteration of PD-L1 expression and PD-1 checkpoint pathway both in IL-23-treated and PD-1 mAb-treated tumor-cell-specific CTLs (Fig. 4B,C).